We are live on ! Find out more

Stoke Therapeutics

STOK

Market cap $1.7B

26.35 USD

-0.06

0.23%

At close Updated Oct 29, 4:00 PM EDT

1 day

-0.23%

5 days

3.21%

1 month

1.82%

3 months

-10.62%

6 months

-18.72%

Year to date

-14.72%

1 year

-16.11%

5 years

15.42%

10 years

3.05%

About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Employees: 170

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.7%

Neutral 68.2%

Negative 9.1%

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulatory submission later that year and a possible launch in early 2028.

Stoke Therapeutics Q3 Earnings Call Highlights

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the third quarter ended September 30, 2026, and provided business updates including progress of the global.

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

Stoke Therapeutics: The Market Misread A Key FDA Win

Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by $420M in cash and a recent $65.7M share sale at a premium to market. The FDA's acceptance of a cognition/behavior endpoint for EMPEROR reduces regulatory risk and differentiates zorevunersen from symptomatic competitors.

Stoke Therapeutics: The Market Misread A Key FDA Win

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting.

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 is an investigational medicine designed to target the underlying cause of Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1.

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

See News Rankings

Price charts implemented using Lightweight Charts™